Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?
The pathogenesis of extrapancreatic tumor hypoglycemia has been related to the secretion of big insulin-like growth factor (IGF) II by the tumor. In 25 of 28 patients with this type of hypoglycemia we found 1.5-8-fold elevated serum levels of immunoreactive big (15-25 kD), but decreased levels of no...
Tallennettuna:
| Julkaisussa: | J Clin Invest |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical Investigation
1992
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC443417/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1281841/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI116152 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|